To save lives and make a difference to society from the early, accurate and actionable detection of trace volatile organic compounds from a single, affordable test.
Ancon is a UK-based company that has developed proprietary technologies for the detection of trace quantities of Volatile Organic Compounds (VOCs).These technologies have a number of important medical applications including breath-based diagnostic testing for cancers, bacteria and viruses, including COVID-19. They also offer significantly improved detection of explosives, narcotics and chemical threats.
Ancon’s technology has the potential to provide faster diagnosis, point of care non-invasive detection, higher sensitivity and a more affordable alternative to current methods in detecting VOCs.
Led by a highly experienced management and scientific team, Ancon is operating in a market that is large and continuing to grow, with opportunities for partners that are scalable and attractive.
Please contact us with any enquiries.
Ancon’s AI/ML technology has the potential to become a powerful tool in medical care and a fundamental part of digital healthcare with applications across multiple disease areas including perioperative infections, MRSA/MSSA, lung cancer and neurodegenerative disease.
With several ongoing clinical studies, Ancon is a potential market leader in the breath-based COVID-19 diagnostics sector.
Why Ancon's Technology Is So Exciting:
Point of need – rapid results on site within 10 minutes
Non-invasive – no injections, anaesthetic or bodily intrusions
Increased accuracy vs reference testing due to powerful ML – powerful proprietary ML means significantly better specificity and sensitivity due to pattern recognition
More specific than currently employed PCR tests – MLBA detects active/infectious viruses and bacteria. PCR detects both active and harmless DNA and RNA fragments
Easy to use – minimal training required
Low cost – enable mass screening for many diseases
Mobile – machine is light weight and portable
Personalised – trending and sequential tests available on an individual by individual basis
AI & ML technology – enables continuous improvements in profiling
Early stage detection of disease